Industry Context — Common BS Fingerprints in Healthcare Providers & Medical Clinics
Generic Claims:
world-class healthcare, your health is our priority, compassionate care, trusted by thousands of patients…
Red Flags:
no CQC registration or equivalent regulatory status, practitioner names without GMC or registration numbers, guaranteed treatment outcomes for complex conditions, testimonials making medical claims…
Semantic Drift Patterns:
homepage claims specialist expertise but services page is general practice, claims evidence-based but promotes unproven treatments, homepage targets complex conditions but offerings are routine screenings, claims NHS and private but private is the only visible option…
Proof Expectations:
CQC registration and rating, GMC or relevant professional registration for all practitioners, named specialist qualifications and training, published fees and pricing transparency…
Fresenius SE & Co. KGaA
(https://fresenius.com) 📸 Data Snapshot: May 30, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Home | FSE (https://fresenius.com)
Title
Home | FSE
H2 Main navigation
H2 News
H2 Annual General Meeting 2026
H2 Library
H2 FOLLOW US
H2 THE HEALTHCARE GROUP
H2 CONTACT US
H2 VISIT US
H3 AI assistant enhances access to Investor Relations information
H3 2026 Annual General Meeting of Fresenius: Shareholders approve all agenda items
H3 2026 Annual General Meeting: Fresenius delivers strong performance in 2025 and proposes 5% increase in dividends
H3 #FutureFresenius: REJUVENATE in action – Excellent start to the year – demonstrating continued strength and resilient performance; Guidance reconfirmed
H3 Fresenius invests in Avelios Medical and further expands its strategic partnership with SAP
H3 #FutureFresenius is paying off: S&P Global Ratings revises outlook for Fresenius SE from stable to positive
H3 Fresenius publishes 2025 Annual Report – REJUVENATE: Delivering accelerated performance for long-term value creation
H3 #FutureFresenius: REJUVENATE in action – Delivering accelerated performance for long-term value creation; 2025 yet another year of strong delivery
H3 Fresenius Supervisory Board extends ahead of schedule CEO Michael Sen’s contract by five years — Christian Pawlu to join Management Board for Fresenius Helios effective July 1, 2026
H3 Fresenius and Phlow Partner to Strengthen U.S. Supply of Essential Medicine
H3 AI in Healthcare: SAP and Fresenius Accelerate Digital Healthcare Delivery
H3 Fresenius advances scalable cell therapy manufacturing with strategic-development agreement
H3 Sale of Austrian project business and spa operations to PORR approved
H3 Fresenius strengthens biomanufacturing capabilities through AI collaboration
H3 Fresenius Launches Denosumab Biosimilars in EU
H3 Katrin Kerner and Christian Wagner to lead Group Communications at Fresenius
H3 Fresenius climbs to 2nd place in governance ranking
H3 Fresenius Q3/25: Disciplined execution drives continued strong performance – guidance raised
NAV_HEADER_HEADING_REPEATED_BODY Annual General Meeting | Fresenius SE & Co. KGaA (https://fresenius.com/annual-general-meeting/)
Title
Annual General Meeting | Fresenius SE & Co. KGaA
Meta
All information on the Fresenius Annual General Meeting: agenda, resolutions, voting results and shareholder documents.
H1 Annual General Meeting
H2 Main navigation
H2 Information on the Annual General Meeting on May 22, 2026
H2 FOLLOW US
H2 THE HEALTHCARE GROUP
H2 CONTACT US
H2 VISIT US
H3 Shareholder Portal of Fresenius SE & Co. KGaA
H3 Countermotions and election proposals
H3 Countermotions
H3 Countermotions
H3 Further information on the AGM 2018
H3 Further information on the AGM 2017
H3 Further information on the AGM 2016
H3 Further information on the AGM 2015
H4 Archive
H4 Countermotions and election proposals
H4 Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)
H4 Countermotions and election proposals
H4 Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)
H4 Counter motions
H4 Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)
H4 Counter motions
H4 Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)
H4 Counter motions
H4 Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)
H5 Counter motions
NAV_HEADER_HEADING_REPEATED_FOOTER Contacts | FSE (https://fresenius.com/contact/)
Title
Contacts | FSE
H1 Contacts
H2 Main navigation
H2 FOLLOW US
H2 THE HEALTHCARE GROUP
H2 CONTACT US
H2 VISIT US
NAV_HEADER_HEADING_REPEATED_BODY Fresenius Kabi | FSE (https://fresenius.com/fresenius-kabi/)
Title
Fresenius Kabi | FSE
H1 Fresenius Kabi
H2 Main navigation
H2 FOLLOW US
H2 THE HEALTHCARE GROUP
H2 CONTACT US
H2 VISIT US
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://fresenius.com) Home | FSE
Resolutions of the 2026 Annual General Meeting Acting together for sustainable impact: Sustainability Highlights Magazine Vol. 3 is online! How Fresenius turns science into better patient care More time for patients thanks to AI in the consulting room FRESENIUS SE & CO. KGaA Resolutions of the 2026 Annual General Meeting Here you will find the resolutions of the 2026 Fresenius Annual General Meeting. More details Acting together for sustainable impact: Sustainability Highlights Magazine Vol. 3 is online! Discover how Fresenius embeds sustainability into its core business and steers impact across clear focus topics – driven by shared responsibility and long‑term value creation. Sustainability Highlights Magazine Vol. 3 How Fresenius turns science into better patient care Explore how Fresenius leverages scientific innovation, collaboration, and evidence-based medicine to improve patient care. Discover inspiring patient stories and research projects from our business segments. Read the story More time for patients thanks to AI in the consulting room With Scribe, our Quirónsalud hospitals are revolutionizing the Spanish healthcare system. The Ai-powered application enhances efficiency and quality while also strengthening the doctor–patient relationship – for more humanity in medicine. Read the story Fresenius Kabi Products for critically and chronically ill patients Fresenius Helios Europe's leading private healthcare provider [H2] News Brief News [H3] AI assistant enhances access to Investor Relations information Today, Fresenius has launched the AI-powered assistant – “AskFRE” – on its Investor Relations (IR) website, marking an important step in advancing its digital capital markets communications. The solution is a joint initiative of the Fresenius AI Center of Excellence and the Investor Relations team.With AskFRE, visitors can now interact with an integrated AI chatbot that provides direct answers to capital market-relevant information. This includes financial results, company updates and other IR content – based exclusively on publicly available Fresenius disclosures.In an increasingly fast-paced and data-driven environment, digital investor relations play a key role in delivering timely, transparent and stakeholder-focused communication. AskFRE supports this ambition by enabling more intuitive access to financial information and tailored user interactions, while reinforcing the consistency and accessibility of Fresenius’ disclosures.With AskFRE, Fresenius underscores its commitment to advancing a best in class digital investor relations experience.AskFRE is now available: https://www.fresenius.com/AskFRE-Your-IR-Assistant May 26, 2026 · Fresenius 2026 Annual General Meeting of Fresenius: Shareholders approve all agenda items [H3] 2026 Annual General Meeting of Fresenius: Shareholders approve all agenda items May 22, 2026 · Fresenius 2026 Annual General Meeting: Fresenius delivers strong performance in 2025 and proposes 5% increase in dividends [H3] 2026 Annual General Meeting: Fresenius delivers strong performance in 2025 and proposes 5% increase in dividends Michael Sen, CEO of Fresenius, emphasized: “In the past financial year, we showed that Fresenius can deliver a strong performance even in an environment where volatility has become the norm.” May 22, 2026 · Fresenius #FutureFresenius: REJUVENATE in action – Excellent start to the year - demonstrating continued strength and resilient performance; Guidance reconfirmed [H3] #FutureFresenius: REJUVENATE in action – Excellent start to the year - demonstrating continued strength and resilient performance; Guidance reconfirmed Michael Sen, CEO of Fresenius: "Fresenius made an excellent start to 2026, delivering performance fully in line with our expectations and leading us to reconfirm our full‑year guidance. May 06, 2026 · Fresenius Fresenius invests in Avelios Medical and further expands its strategic partnership with SAP [H3] Fresenius invests in Avelios Medical and further expands its strategic partnership with SAP Fresenius, together with SAP, is investing in Avelios Medical, a company developing a next-generation, cloud-native hospital information system. May 06, 2026 · Fresenius #FutureFresenius is paying off: S&P Global Ratings revises outlook for Fresenius SE from stable to positive [H3] #FutureFresenius is paying off: S&P Global Ratings revises outlook for Fresenius SE from stable to positive S&P Global Ratings (S&P), a globally recognized credit rating agency today revised its credit outlook for Fresenius SE from stable to positive. April 08, 2026 · Fresenius Brief News [H3] Fresenius publishes 2025 Annual Report – REJUVENATE: Delivering accelerated performance for long-term value creation Today, Fresenius published its 2025 Annual Report. As announced in late February 2026, 2025 marked another strong year of performance and the launch of the current phase of the #FutureFresenius strategy: Rejuvenate. Despite headwinds, the healthcare group achieved its outlook, which was raised twice during the year. Group revenue before special items rose to €22.6 billion, with organic growth of 7%, while constant currency Core EPS (excluding FMC) increased by 12%. “Over the past three years, we have successfully implemented our #FutureFresenius strategy and created a new Fresenius that is innovative, relevant, resilient, and adaptable. At the same time, we have significantly bolstered our company’s economic strength. We aim to build on this strong foundation,” said Michael Sen, Chairman of the Management Board of Fresenius. The 2025 Annual Report demonstrates how Fresenius is creating sustainable value for all stakeholders by executing its #FutureFresenius strategy. It includes the Sustainability Statement in accordance with the European Sustainability Reporting Standards (ESRS), and is available as a PDF and as an interactive online version in German and English. The online report features additional business stories and includes a video statement from CEO Michael Sen. March 25, 2026 · Fresenius #FutureFresenius: REJUVENATE in action – Delivering accelerated performance for long-term value creation; 2025 yet another year of strong delivery [H3] #FutureFresenius: REJUVENATE in action – Delivering accelerated performance for long-term value creation; 2025 yet another year of strong delivery February 25, 2026 · Fresenius Fresenius Supervisory Board extends ahead of schedule CEO Michael Sen’s contract by five years --- Christian Pawlu to join Management Board for Fresenius Helios effective July 1, 2026 [H3] Fresenius Supervisory Board extends ahead of schedule CEO Michael Sen’s contract by five years --- Christian Pawlu to join Management Board for Fresenius Helios effective July 1, 2026 The Fresenius Supervisory Board has unanimously extended ahead of schedule the mandate of CEO Michael Sen (57) by five years. This will help to ensure continuity in the company’s leadership for the next phase in its #FutureFresenius strategy. His contract will now run until 2031.Wolfgang Kirsch, Chair of the Supervisory Board of Fresenius, said: “Michael Sen has been instrumental in driving the company’s development with #FutureFresenius in the past three years. Today, Fresenius is more innovative and relevant – well positioned to leverage the significant opportunities in the healthcare industry. Michael Sen and his team have placed Fresenius on a growth path offering long-term profitability that benefits all stakeholders. We want to maintain this continuity. Both the Supervisory Board and I personally look forward to continuing our collaboration in the coming years.”“I would like to thank the Supervisory Board for its trust and look forward to continuing to work with all Supervisory Board members, my management team, and our outstanding employees as well as our customers, partners, and shareholders. Over the past few years, we have made the company more innovative while remaining focused on delivering profitable growth. Today, Fresenius is more relevant than ever before. We want to continue this success story. In times of fundamental change shaped by rapid advances in new technologies such as AI and a transactional world order, we bear even greater responsibility as a leading global healthcare company. Now more than ever, our goal is to provide high-quality, reliable healthcare while making healthcare systems even more efficient and resilient,” adds Michael Sen, CEO of Fresenius.Dr. Christian Pawlu succeeds Robert MöllerThe Fresenius Supervisory Board has also unanimously appointed Dr. Christian Pawlu (48) to the Fresenius Management Board, effective July 1, 2026. He will oversee the businesses of Fresenius Helios, which includes the two private hospital chains, Quirónsalud in Spain and Helios Kliniken in Germany. He will succeed Robert Möller (59) on the Management Board, who will establish the company’s Office of the Management in Berlin and Brussels.“On behalf of the Supervisory Board, I would like to sincerely thank Robert Möller for the excellent cooperation and successful leadership of Fresenius Helios in recent years. Through the formation of medical clusters and the focus on digitalization and excellent patient care, the two hospital chains are excellently positioned in Germany and Spain. I am therefore delighted that Robert Möller will continue to contribute his expertise to the company,” says Wolfgang Kirsch. He adds: “With Christian Pawlu, we have been able to acquire a physician and strategist with a broad international network for the Group’s Management Board. I am especially pleased that we could find an outstanding internal candidate who has already contributed significantly to the hospital business as Chief Operating Officer of Fresenius Helios. I wish Christian Pawlu a strong start in his new role.”Michael Sen (57) has been CEO of Fresenius since October 1, 2022. He is also Chairman of the Supervisory Board of the listed dialysis provider Fresenius Medical Care. In April 2021, Michael Sen was appointed CEO of Fresenius Kabi. Before joining Fresenius, he was a member of the Management Board at Siemens AG, responsible for the healthcare and energy business. He took Siemens Healthineers public during this time. Prior to this, he was Chief Financial Officer at the energy group E.ON SE.Dr. Christian Pawlu has been Chief Operating Officer (COO) of Helios in Germany since March 2025, and in September 2025 expanded his responsibilities as COO of Fresenius Helios including Helios in Germany and Quirónsalud in Spain. Prior to this, he served as Head of Corporate Development at Fresenius after joining Fresenius Kabi in Bad Homburg as Head of Corporate Development in April 2021. From 2022 to 2025, he was a member of the Supervisory Board of the Fresenius subsidiary mAbxience, based in Spain. In his early career, Christian Pawlu was a member of Sandoz Group AG’s Executive Board, CEO of a private high-tech start-up, and a partner at McKinsey & Company management consultancy. February 25, 2026 · Fresenius Brief News [H3] Fresenius and Phlow Partner to Strengthen U.S. Supply of Essential Medicine Fresenius Kabi, an operating company of Fresenius, has entered a first-of-its-kind partnership with U.S. manufacturer Phlow Corp. to establish a fully domestic, end-to-end supply chain for Epinephrine Injection, USP — an FDA designated essential medicine frequently at risk of shortage in the United States. Under the collaboration, Phlow will produce the U.S.-based API, while Fresenius Kabi manufactures the finished doses for hospitals and clinics across the country. With this initiative, Fresenius advances its local-for-local manufacturing strategy and supports national efforts to strengthen pharmaceutical security. The partnership reinforces the ambitions of #FutureFresenius as it expands Fresenius’ role as a leading global provider of lifesaving therapies, advancing resilient manufacturing that improves patient care and health-system stability. Pending regulatory approvals, epinephrine produced through this collaboration could be available to U.S. hospitals in 2027. February 09, 2026 · Fresenius Kabi AI in Healthcare: SAP and Fresenius Accelerate Digital Healthcare Delivery [H3] AI in Healthcare: SAP and Fresenius Accelerate Digital Healthcare Delivery January 19, 2026 · Fresenius Brief News [H3] Fresenius advances scalable cell therapy manufacturing with strategic-development agreement Fresenius has entered into a strategic development agreement with TQ Therapeutics to support the scalable and efficient manufacturing of cell and gene therapies, strengthening its role in advancing next generation treatments. Under the agreement, operating company Fresenius Kabi receives an exclusive license to integrate TQ Therapeutics’ proprietary cell selection technology into its Cue® Cell Processing System. The combined solution aims to isolate high purity T cells in less than two hours, helping therapy developers streamline processes and accelerate development. The collaboration is in line with Fresenius’ #FutureFresenius strategy to focus on high value healthcare platforms, strengthen core technologies, and improve patient access through operational excellence and innovation. By enabling more automated, robust, and scalable cell therapy manufacturing, Fresenius Kabi and TQ Therapeutics aim to support the broader adoption of cell and gene therapies, including applications closer to the point of care. January 14, 2026 · Fresenius Kabi Brief News [H3] Sale of Austrian project business and spa operations to PORR approved The sale of the Austrian project business and spa operations of VAMED Vitality World to PORR, announced by Fresenius in October 2025, has received the necessary approvals and will be completed on December 31, 2025. December 23, 2025 · Fresenius Brief News [H3] Fresenius strengthens biomanufacturing capabilities through AI collaboration mAbxience, a Fresenius entity, has entered into a collaboration with HP Inc. to develop an artificial intelligence (AI) solution aimed at making biomanufacturing more efficient and reliable.The joint project uses AI and digital-twin technology to model and optimize key steps in the production of monoclonal antibodies and biosimilars. By simulating critical cell-culture parameters and predicting process outcomes, the system is designed to support more consistent yields, faste
15000 chars
SUB-PAGE (https://fresenius.com/annual-general-meeting/) Annual General Meeting | Fresenius SE & Co. KGaA
[H1] Annual General Meeting To archive Contact Nick Stone Senior Vice President Investor Relations Head of Investor Relations T: +49 (0) 6172 608-97033 nick.stone@fresenius.com Share Price FRESENIUS SE & CO. KGaA Data is delayed by 15 minutes. Share Price Information Shareholder Portal [IMG: shareholder portal] To Shareholder Portal Related Links Interactive Tool Total Return Calculator FAQ Shares and dividends Annual General Meeting The Annual General Meeting of Fresenius SE & Co. KGaA took place on May 22, 2026, at the Congress Center, Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main, Germany. [H3] Shareholder Portal of Fresenius SE & Co. KGaA Shareholders can use the Shareholder Portal to exercise their voting right by electronic postal ballot, authorize third parties or authorize and instruct the proxies nominated by the Company. The login credentials to the Shareholder Portal are indicated on the admission ticket shareholders receive after due registration to the Annual General Meeting. To Shareholder Portal Internet broadcast The opening of the Annual General Meeting by the Chairman of the Supervisory Board, Wolfgang Kirsch, and the report by the Chairman of the Management Board, Michael Sen, were broadcast publicly. [H2] Speech of CEO Michael Sen Watch replay CEO Speech (PDF, 270KB) Presentation (PDF, 6.30MB) Download All [H2] Information on the Annual General Meeting on May 22, 2026 Chairman Letter and Speech Wolfgang Kirsch Chairman Letter (PDF, 294KB) Chairman Speech (PDF, 186KB) Download All [H2] Invitation / Agenda Agenda (PDF, 329KB) Information for shareholders Information on rights of shareholders (PDF, 187KB) Form for shareholders to authorize a proxy and to issue instructions (PDF, 245KB) Privacy Notice (PDF, 25KB) Information pursuant to § 125 Stock Corporation Act (AktG) in conjunction with the Commission Implementing Regulation (EU) 2018/1212 (“EU-IR”) (PDF, 183KB) Information on the Agenda items Financial Statements and Management Report of Fresenius SE & Co. KGaA as of December 31, 2025 (HGB) (PDF, 7.68MB) Fresenius Group Annual Report 2025 (PDF, 14.08MB) Compensation Report 2025 (PDF, 616KB) Proposal of the General Partner and the Supervisory Board on the allocation of the distributable profit for the financial year 2025 (Agenda item 2) (PDF, 118KB) Further Information on agenda item 7 – Remuneration of the Supervisory Board (PDF, 85KB) General Partner’s report regarding Agenda item 8 (PDF, 87KB) General Partner’s report regarding Agenda item 10 (PDF, 86KB) General Partner’s report regarding Agenda items 11 and 12 (PDF, 136KB) Further information on Agenda item 13 – Frequently Asked Questions (FAQ) on the Conversion from Bearer Shares to Registered Shares (PDF, 107KB) Explanatory Report of the General Partner of Fresenius SE & Co. KGaA (Fresenius Management SE) on the Statements pursuant to Section 289a Para. 1, Section 315a Para. 1 of the German Commercial Code (Handelsgesetzbuch – HGB) (PDF, 139KB) Articles of Association Fresenius SE & Co. KGaA (May 23, 2025) (PDF, 174KB) Revised version of the Articles of Association with amendments highlighted - Amendments to the Articles of Association regarding Agenda items 7–10 and 13–15 (PDF, 169KB) Additional Information Meeting Participation by individual Supervisory Board member 2025 (PDF, 107KB) 2025 SASB Mapping (PDF, 309KB) Information pursuant to Table 8 of the Commission Implementing Regulation (EU) 2018/1212 (PDF, 494KB) Further publications Dividend announcement (PDF, 473KB) Voting results 2026 (PDF, 75KB) Download All [H3] Countermotions and election proposals Below, you find the countermotions from a shareholder within the meaning of section 126 of the German Stock Corporation Act (Aktiengesetz) on items 3 and 4 of the agenda of the Annual General Meeting of Fresenius SE & Co. KGaA on May 22, 2026. [H2] Countermotions and election proposals Annual General Meeting 2026 Countermotions from shareholders (PDF, 325KB) Download All [H4] Archive 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 The Annual General Meeting of Fresenius SE & Co. KGaA took place on May 23, 2025, at the Congress Center, Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main, Germany. Annual General Meeting on May 23, 2025 [H2] Speech of CEO Michael Sen Watch replay Speech of CEO (PDF, 172KB) Presentation (PDF, 8.84MB) Download All [H2] Chairman Letter Wolfgang Kirsch Chairman Letter (PDF, 242KB) Download All [H2] Invitation / Agenda Agenda (PDF, 1.30MB) Download All [H2] Information for shareholders Information on rights of shareholders (PDF, 184KB) Form for shareholders to authorize a proxy and to issue instructions (PDF, 157KB) Privacy Notice (PDF, 69KB) Information pursuant to § 125 Stock Corporation Act (AktG) in conjunction with the Commission Implementing Regulation (EU) 2018/1212 (“EU-IR”) (PDF, 241KB) Information on the agenda items Financial Statements and Management Report of Fresenius SE & Co. KGaA as of December 31, 2024 (HGB) (PDF, 2.92MB) Fresenius Group Annual Report 2024 (PDF, 11.26MB) Compensation Report 2024 (PDF, 589KB) Proposal of the General Partner and the Supervisory Board on the allocation of the distributable profit for the financial year 2024 ended on December 31, 2024 (Agenda item 2) (PDF, 83KB) Explanatory Report of the General Partner of Fresenius SE & Co. KGaA (Fresenius Management SE) on the Statements pursuant to Section 289a Para. 1, Section 315a Para. 1 of the German Commercial Code (Handelsgesetzbuch – HGB) (PDF, 151KB) Further Information on agenda item 7 – Remuneration of the Supervisory Board (PDF, 83KB) Further information on agenda items 8 and 9 – CVs (PDF, 1.08MB) Articles of Association Fresenius SE & Co. KGaA (April 2024) (PDF, 171KB) Additional Information Meeting Participation by individual Supervisory Board member 2024 (PDF, 142KB) 2024 SASB Mapping (PDF, 163KB) Further publications Dividend announcement (PDF, 95KB) Voting results 2025 (PDF, 35KB) Download All [H4] Countermotions and election proposals Below, you find the countermotions from a shareholder within the meaning of section 126 of the German Stock Corporation Act (Aktiengesetz) on items 3 and 10 of the agenda of the Annual General Meeting of Fresenius SE & Co. KGaA on May 23, 2025. [H2] Countermotions and election proposals Annual General Meeting 2025 Countermotions from shareholders (PDF, 138KB) Download All [H4] Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act) At the time the General Meeting is convened, 563,237,277 ordinary shares out of a total of 563,237,277 ordinary shares issued carry rights of participation and voting rights. The Annual General Meeting of Fresenius SE & Co. KGaA took place on Friday, 17 May 2024 at the Congress Center, Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main, Germany. Annual General Meeting on May 17, 2024 [H2] Speech of CEO Michael Sen Speech of CEO (PDF, 350KB) Presentation (PDF, 5.45MB) Download All [H2] Chairman Letter Wolfgang Kirsch Chairman Letter (PDF, 274KB) Download All [H2] Invitation / Agenda Agenda (PDF, 1,004KB) Information for shareholders Information on rights of shareholders (PDF, 138KB) Form for shareholders to authorize a proxy and to issue instructions (PDF, 173KB) Privacy Notice (PDF, 70KB) Information pursuant to § 125 Stock Corporation Act (AktG) in conjunction with the Commission Implementing Regulation (EU) 2018/1212 (“EU-IR”) (PDF, 197KB) Information on the agenda items Financial Statements and Management Report of Fresenius SE & Co. KGaA as of December 31, 2023 (HGB) (PDF, 2.26MB) Fresenius Group Annual Report 2023 (PDF, 9.23MB) Compensation Report 2023 (PDF, 294KB) Explanatory Report of the General Partner of Fresenius SE & Co. KGaA (Fresenius Management SE) on the Statements pursuant to Section 289a Para. 1, Section 315a Para. 1 of the German Commercial Code (Handelsgesetzbuch – HGB) (PDF, 128KB) Articles of Association Fresenius SE & Co. KGaA (June 15, 2023) (PDF, 195KB) Additional Information Meeting Participation by individual Supervisory Board member 2023 (PDF, 83KB) 2023 SASB Mapping (PDF, 214KB) 2023 TCFD Index (PDF, 104KB) Download All [H2] Further publications Voting results 2024 (PDF, 269KB) Download All [H3] Countermotions Currently, there are no countermotions. Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act) At the time the General Meeting is convened, 563,237,277 ordinary shares out of a total of 563,237,277 ordinary shares issued carry rights of participation and voting rights. The virtual Annual General Meeting of Fresenius SE & Co. KGaA took place on May 17, 2023. Virtual Annual General Meeting on May 17, 2023 [H2] Speech of CEO Michael Sen Watch replay Speech of CEO (PDF, 397KB) Download All [H2] Invitation / Agenda Agenda (PDF, 3.44MB) Information for shareholders Information on rights of shareholders (PDF, 162KB) Form for shareholders to authorize a proxy and to issue instructions (PDF, 152KB) Privacy Notice (PDF, 99KB) Information pursuant to § 125 Stock Corporation Act (AktG) in conjunction with the Commission Implementing Regulation (EU) 2018/1212 (“EU-IR”) (PDF, 193KB) Recommendations/instructions for electronic connection via video (PDF, 107KB) Information on the agenda items Financial Statements and Management Report of Fresenius SE & Co. KGaA as of December 31, 2022 (HGB) (PDF, 2.44MB) Fresenius Group Annual Report 2022 (PDF, 10.87MB) Compensation Report 2022 (PDF, 2.56MB) Proposal of the General Partner and the Supervisory Board on the allocation of the distributable profit for the financial year 2022 ended on December 31, 2022 (Agenda item 2) (PDF, 93KB) Explanatory Report of the General Partner of Fresenius SE & Co. KGaA (Fresenius Management SE) on the Statements pursuant to Section 289a Para. 1, Section 315a Para. 1 of the German Commercial Code (Handelsgesetzbuch – HGB) (PDF, 154KB) Further information regarding the Compensation System 2023+ (Agenda item 7) (PDF, 551KB) Articles of Association Fresenius SE & Co. KGaA (July 6, 2022) (PDF, 168KB) Additional Information Meeting Participation by individual Supervisory Board member 2022 (PDF, 104KB) 2022 SASB Mapping (PDF, 206KB) 2022 TCFD Index (PDF, 73KB) Further publications Dividend announcement (PDF, 119KB) Voting results 2023 (PDF, 285KB) Download All [H3] Countermotions Currently, there are no countermotions. Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act) At the time the General Meeting is convened, 563,237,277 ordinary shares out of a total of 563,237,277 ordinary shares issued carry rights of participation and voting rights. The virtual Annual General Meeting 2022 of Fresenius SE & Co. KGaA took place on May 13, 2022. Virtual Annual General Meeting on May 13, 2022 [H2] Speech of CEO Stephan Sturm Watch replay Speech of CEO (PDF, 207KB) Presentation (PDF, 4.00MB) Download All [H2] Invitation / Agenda Agenda (PDF, 4.90MB) Information for shareholders Information on rights of shareholders (PDF, 128KB) Form for shareholders to authorize a proxy and to issue instructions (PDF, 173KB) Privacy Notice (PDF, 71KB) Information pursuant to § 125 Stock Corporation Act (AktG) in conjunction with the Commission Implementing Regulation (EU) 2018/1212 (“EU-IR”) (PDF, 194KB) Information on scrip dividend Supplemented prospectus exemption document, 2nd supplement (PDF, 258KB) Supplemented prospectus exemption document, 1st supplement (PDF, 255KB) Prospectus exemption document (PDF, 328KB) Information document (PDF, 243KB) Subscription Offer (PDF, 212KB) Announcement of subscription price (PDF, 107KB) Information on the agenda item Financial Statements and Management Report of Fresenius SE & Co. KGaA as of December 31, 2021 (HGB) (PDF, 2.14MB) Fresenius Group Annual Report 2021 (PDF, 12.98MB) Compensation Report 2021 (PDF, 4.71MB) Proposal of the General Partner and the Supervisory Board on the allocation of the distributable profit for the financial year 2021 ended on December 31, 2021 (Agenda item 2) (PDF, 77KB) General Partner’s written report regarding Item 9 of the agenda (PDF, 94KB) General Partner’s written report regarding Item 10 of the agenda (PDF, 96KB) General Partner’s written report regarding Item 11 and 12 of the agenda (PDF, 122KB) Explanatory Report of the General Partner of Fresenius SE & Co. KGaA (Fresenius Management SE) on the Statements pursuant to Section 289a Para. 1, Section 315a Para. 1 of the German Commercial Code (Handelsgesetzbuch – HGB) (PDF, 149KB) Articles of Association Fresenius SE & Co. KGaA (PDF, 253KB) Additional Information Further information on the Compensation Report 2021 (PDF, 674KB) Meeting Participation by individual Supervisory Board member 2021 (PDF, 96KB) 2021 SASB Mapping (PDF, 190KB) 2021 TCFD Index (PDF, 119KB) Further publications Dividend announcement (PDF, 107KB) Voting results 2022 (PDF, 288KB) Download All [H4] Countermotions and election proposals Below, you find the count
15000 chars
SUB-PAGE (https://fresenius.com/contact/) Contacts | FSE
[H1] Contacts Related Links Group Overview The Healthcare Group worldwide Fresenius-Websites Do you have questions regarding our company and our products and services? Our experts will be happy to help. Fresenius SE & Co. KGaAElse-Kröner-Str. 161352 Bad HomburgGermanyT: +49 6172 608-0 Postal address:Fresenius SE & Co. KGaA61346 Bad HomburgGermany How to get here (PDF, 2.01 MB) Route planner Contacts for investors and analysts Nick Stone Senior Vice President Investor Relations Head of Investor Relations T: +49 (0) 6172 608-97033 nick.stone@fresenius.com Karen Janek Assistant Investor Relations T: +49 (0) 6172 608-2487 karen.janek@fresenius.com Florian Feick Vice President Investor Relations Deputy Head of Investor Relations T: +49 (0) 6172 608-5167 florian.feick@fresenius.com Stefanie Drees Director Investor Relations T: +49 (0) 6172 608-5211 stefanie.drees@fresenius.com Michael Otto Director Investor Relations T: +49 (0) 6172 608-2419 michael.otto@fresenius.com Elisabeth Truckenbrodt Director Investor Relations T: +49 (0) 6172 608-2486 elisabeth.truckenbrodt@fresenius.com Felix Klein Director Investor Relations T: +49 (0) 6172 608-96484 felix.klein@fresenius.com Kacper Boborykin Director Investor Relations (US based) T: +1 224 566 1998 kacper.boborykin@fresenius.com Mara Sinsel Senior Manager Investor Relations T: +49 (0) 6172 608-96538 mara.sinsel@fresenius.com Luca Thorißen Senior Manager Investor Relations T +49 6172 608-97049 luca.thorissen@fresenius.com Elisabeth Jung Senior Manager Investor Relations T: +49 (0) 6172 608-2421 elisabeth.jung@fresenius.com Annette Hainz Manager Investor Relations T: +49 (0) 6172 608-2604 annette.hainz@fresenius.com Contacts for the media Alexandra Graulich Secretary Group Communications T: +49 (0) 6172 608-2501 alexandra.graulich@fresenius.com Contacts for Corporate Topics Timo Lindemann T +49 (0) 6172 608-7939 timo.lindemann@fresenius.com Leif Heussen T +49 (0) 6172 608-4030 leif.heussen@fresenius.com Annette Schönleber T: +49 (0) 6172 608-96847 annette.schoenleber@fresenius.com Sabine Polte (on parental leave) T: +49 (0) 6172 608-2395 sabine.polte@fresenius.com Contacts for Fresenius Kabi Nicole Meier T +49 (0) 6172 686-2394 nicole.meier@fresenius.com Tim-Arne Kuehrt T +49 (0) 6172 686-4112 tim.kuehrt@fresenius.com Contacts for Fresenius Helios Steffen Rinas T: +49 (0) 6172 608-6698 steffen.rinas@fresenius.com Birgit Gugath T +49 (0) 173 28 12 169 birgit.gugath@helios-gesundheit.de Franziska Vallentin T +49 (0) 151 65 21 99 81 franziska.vallentin@helios-gesundheit.de Contacts for applicants If you have questions regarding our application process or our career opportunities please contact us at karriere@fresenius.com. You can find detailed contact information on our careers website. Contacts for health care professionals and patients For information on specific products and services, please directly contact our business segments: Fresenius Kabi Infusion therapy, clinical nutrition and transfusion technology Fresenius Helios (German only) Hospitals and health care prevention Contacts for Governmental Affairs & Public Policy Joachim Weith Senior Vice President Governmental Affairs & Public Policy T: +49 (0) 6172 608-2101 GAPP@fresenius.com Daniela Eyrich Team Assistant Governmental Affairs & Public Policy T: +49 (0) 6172 608-2302 daniela.eyrich@fresenius.com Contacts for questions about sustainability If you have any questions about sustainability, please contact us at the following address: sustainability@fresenius.com Detailed information on sustainability can be found at Responsibility. Contact for procurement inquiries If you have any questions about procurement, please contact us at the following address: zentraleinkauf@fresenius.com Related Links Group Overview The Healthcare Group worldwide Fresenius-Websites
5116 chars
SUB-PAGE (https://fresenius.com/fresenius-kabi/) Fresenius Kabi | FSE
[H1] Fresenius Kabi Industrial production of infusion solutions at Fresenius Kabi's plant in Friedberg. Contact Fresenius Kabi AG Else-Kröner-Str. 1 61352 Bad Homburg Germany T: +49 6172 686-0 communication@fresenius-kabi.com Fresenius Kabi Related Links Infusion Therapy Clinical Nutrition Transfusion Technology Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients. Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition portfolio includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, Fresenius Kabi offers vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more. Fresenius Kabi employs over 40,000 people worldwide. In 2025 the company reported sales of more than €8.5 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group and one of the two Operating Companies of Fresenius. Contact Fresenius Kabi AG Else-Kröner-Str. 1 61352 Bad Homburg Germany T: +49 6172 686-0 communication@fresenius-kabi.com Fresenius Kabi Related Links Infusion Therapy Clinical Nutrition Transfusion Technology
1699 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
11Review mentions (all pages)
8External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 10 | 2 |
| /annual-general-meeting/ | 0 | 2 |
| /contact/ | 0 | 2 |
| /fresenius-kabi/ | 1 | 2 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage — no schema detected (entity gap)
/annual-general-meeting/ — no schema detected (entity gap)
/contact/ — no schema detected (entity gap)
/fresenius-kabi/ — no schema detected (entity gap)
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Healthcare Providers & Medical Clinics
38.2 Avg BS
Based on 352 businesses audited.
BS Detector
Healthcare Providers & Medical Clinics BS: Fresenius SE & Co. KGaA (fresenius.com)
https://fresenius.com
📍 Industry: Healthcare Providers & Medical Clinics
20
BS / 100
Fresenius provides a masterclass in corporate substance, eschewing common healthcare marketing tropes for rigorous financial and strategic disclosure. The low BS score reflects a business that treats its website as a transparency portal rather than a persuasion engine. It is a highly credible digital footprint for a global healthcare giant.
Info Density
Power-words vs. Substance ratio.
4
13% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
2
10% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
4
20% BS
Commodity Fingerprint
Detection of industry clichés/templates.
5
33% BS
Identity & Authority
Expert verifiability & Schema depth.
5
33% BS
Implement comprehensive Organization and Person schema to bridge the technical authority gap and link board members to their professional footprints. Populate the missing meta descriptions for better search-engine signal alignment. Convert the governance ranking claim into a direct outbound proof link to the third-party source. Ensure the review_count on the homepage is mapped to a visible, verifiable third-party review platform to avoid trust theatre flags.
The site fits the Healthcare Providers & Medical Clinics category at a conglomerate level, focusing on clinical nutrition, infusion therapy, and hospital management via Fresenius Helios. The content is heavily weighted toward corporate governance and investor relations, which is appropriate for a publicly traded KGaA entity.
“The score of 20 is primarily driven by technical authority gaps (missing schema) and the use of industry-standard corporate jargon. The site performed exceptionally well in Information Density and Semantic Coherence, scoring near zero for BS in those categories due to its heavy reliance on dated, quantified news and legal documentation.”
Verified Analysis Date: May 30, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from Fresenius SE & Co. KGaA, captured on May 30, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Fresenius SE & Co. KGaA: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://fresenius.com to view the most current version of its content and learn from the source what this company is about and what it offers.